Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Cyclophosphamide
Related studies linked through entity extraction aliases.
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
- Status
- RECRUITING
- Phase
- PHASE1
A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
- Status
- WITHDRAWN
- Phase
- PHASE2
Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide
- Status
- RECRUITING
- Phase
- PHASE2
Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors
- Status
- NOT_YET_RECRUITING
- Phase
- EARLY_PHASE1
Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
- Status
- RECRUITING
- Phase
- PHASE2
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
- Status
- RECRUITING
- Phase
- PHASE2
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Status
- RECRUITING
- Phase
- PHASE2
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
- Status
- RECRUITING
- Phase
- PHASE3
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Treatment of Moderate to Severe Refractory Crohn's Disease
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2